scholarly journals Comparing cell‐free circulating tumor DNA mutational profiles of disease‐free and nonresponders patients with oropharyngeal squamous cell carcinoma

2020 ◽  
Vol 5 (5) ◽  
pp. 868-878
Author(s):  
Alok R. Khandelwal ◽  
Adam H. Greer ◽  
Mickie Hamiter ◽  
Janmaris Marin Fermin ◽  
Thomas McMullen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Circulating Tumor Dna ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Disease Free ◽  
Tumor Dna

scholarly journals P2.03b-023 Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)

2017 ◽  
Vol 12 (1) ◽  
pp. S947-S948
Author(s):  
Vincent Lam ◽  
Hai Tran ◽  
Kimberly Banks ◽  
Waree Rinsurongkawong ◽  
Vassiliki Papadimitrakopoulou ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Squamous Cell Carcinoma ◽  
Circulating Tumor Dna ◽  
Genomic Profiling ◽  
Cancer Genes ◽  
Tumor Dna

Clinical implications of monitoring circulating tumor DNA in early- and late-stage non-small cell lung cancer patients.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20607-e20607
Author(s):  
Muyun Peng ◽  
Lihan Chin ◽  
Qi Huang ◽  
Wei Yin ◽  
Sichuang Tan ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Somatic Mutations ◽  
Residual Disease ◽  
Lung Squamous Cell Carcinoma ◽  
Circulating Tumor Dna ◽  
Small Cell Lung ◽  
Tumor Dna

e20607 Background: Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, and the most common types of NSCLC are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. The development of noninvasive methods to monitor circulating tumor DNA (ctDNA) continues to be a major challenge in NSCLC. Methods: We investigated if detection of ctDNA after resection of NSCLC identifies the patients with risk of relapse, and furthermore, informs about response to management.In this cohort study, high-throughput 168 target-gene capture technology and high-sensitivity circulating single molecule amplification and re-sequencing technology (cSMART) were used to detect the somatic mutations in tissues and plasma of patients with NSCLC, respectively. Moreover, ctDNA somatic mutations were used to monitor changes in minimal residual disease during a follow-up period. Results: A total of 169 patients with lung squamous cell carcinoma and adenocarcinoma were included. Detectable levels of ctDNA were present in 60.7% of patients with stage I and 68.8% of patients with late-stage. In patients not treated with adjuvant chemotherapy, ctDNA was detected preoperatively in 46 of 81 (56.8%) patients, 14 (30.4%) of whom had recurred at follow-up of 44 months; recurrence occurred in only 2 (5.7 %) of 35 patients with negative ctDNA. Serial ctDNA status changed from positive to negative during the initial phase of post operation in four patients. Then, ctDNA became positive again after 2 weeks to 3 months, all the four patients with relapse during the follow-up of 44 months. Conclusions: Detection of ctDNA supplies evidence of residual disease and identifies patients at risk of relapse. These observations have implications for the intervention of lung squamous cell carcinoma and adenocarcinoma patients.

Sign in / Sign up

Export Citation Format

Share Document